

WHAT IS CLAIMED IS:

- 5 1. A method of modulating inflammation in a subject comprising:
administering a peptide agent comprising a sequence
corresponding to a partial-length T20/DP178 or T21/DP107FPR
antagonist.
- 10 2. An isolated complex comprising: a peptide agent having a
sequence that corresponds to T20/DP178, T21/DP107, or a
conservative variant or functional fragment thereof bound to an
FPR member.
- 15 3. A method of modulating an inflammatory response in a subject
comprising:
identifying a subject in need of a peptide agent that
interacts with an FPR member; and
administering to said subject an inflammatory response
modulating-amount of said peptide agent, wherein said peptide
agent comprises a sequence that corresponds to T20/DP178,
T21/DP107, or a conservative variant or functional fragment
thereof.
- 20 4. A method of modulating an inflammatory response in a subject
comprising:
administering to said subject an inflammatory response
modulating-amount of a peptide agent having a sequence that
corresponds to T20/DP178, T21/DP107, or a conservative variant
or functional fragment thereof; and
- 25 measuring the effect of said peptide agent as a ligand that
interacts with an FPR member.
- 30 5. A method of making a pharmaceutical product comprising:
providing a peptide agent having a sequence
corresponding to T20/DP178, T21/DP107, or a
conservative variant or functional fragment thereof;

